The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year. Placental malaria (PM) is one such manifestation in which Pf infected erythrocytes (IE) bind to chondroitin sulphate A (CSA) through expression of VAR2CSA, a parasite-derived antigen. Protection against PM is mediated by antibodies that inhibit binding of IE in the placental intervillous space. VAR2CSA is a large antigen incompatible with large scale recombinant protein expression. Vaccines based on sub-units encompassing the functionally constrained receptor-binding domains may, theoretically, circumvent polymorphisms, reduce the risk of escape-mutants and induce cross-reactive antibodies. However, the sub-unit composition and small differences in the borders, may lead to exposure of novel immuno-dominant antibody epitopes that lead to non-functional antibodies, and furthermore influence the folding, stability and yield of expression. Candidate antigens from the pre-clinical development expressed in High-Five insect cells using the baculovirus expression vector system were transitioned into the Drosophila Schneider-2 cell (S2) expression-system compliant with clinical development. The functional capacity of antibodies against antigens expressed in High-Five cells or in S2 cells was equivalent. This enabled an extensive down-selection of S2 insect cell-expressed antigens primarily encompassing the minimal CSA-binding region of VAR2CSA. In general, we found differential potency of inhibitory antibodies against antigens with the same borders but of different var2csa sequences. Likewise, we found that subtle size differences in antigens of the same sequence gave varying levels of inhibitory antibodies. The study shows that induction of a functional response against recombinant subunits of the VAR2CSA antigen is unpredictable, demonstrating the need for large-scale screening in order to identify antigens that induce a broadly strain-transcending antibody response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702 · cited 1×
“A major breakthrough was the discovery that the conserved PfEMP1 antigen VAR2CSA enables IE to bind to chondroitin sulphate A (CSA) on syncytiotrophoblasts and thereby to accumulate in the placenta [9].”
BackgroundSelf-citationMaternal antibodies block malaria
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998) · Nature · doi:10.1038/27570 · Cited by 659
Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I., & Marsh, K. (1998) · Nature Medicine · doi:10.1038/nm0398-358 · Cited by 645 · cited 1×
“However, the var genes that encode PfEMP1 are polymorphic and naturally-acquired protection relies on the infection-induced acquisition of a broad repertoire of anti-PfEMP1 antibodies during early childhood [7,8].”
BackgroundRicke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D., Riley, E. M., Theander, T. G., & Hviid, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3309 · Cited by 303
Self-citationDuffy, P. E., & Fried, M. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6620-6623.2003 · Cited by 260 · cited 2×
“As protection against PM is associated with antibodies that inhibit the binding of infected erythrocytes to CSA [14,15], the primary goal is the development of an adhesion-blocking vaccine, although opsonizing antibodies may also play a role in protection [16].”
BackgroundNielsen, M. A., Staalsoe, T., Kurtzhals, J. A. L., Goka, B. Q., Dodoo, D., Alifrangis, M., Theander, T. G., Akanmori, B. D., & Hviid, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3444 · Cited by 207
Self-citationClausen, T. M., Christoffersen, S., Dahlbäck, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbæk, M. Ø., Andersen, D., Berisha, B., Ditlev, S. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348839 · Cited by 173 · cited 2×
“ID1-ID2a antigen increasing the risk of containing non-functional B-cell epitopes [17].”
BackgroundSelf-citationBarfod, L., Bernasconi, N. L., Dahlbäck, M., Jarrossay, D., Andersen, P. H., Salanti, A., Ofori, M. F., Turner, L., Resende, M., Nielsen, M. A., et al. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05503.x · Cited by 110
Self-citationProtective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin
Ndam, N. T., Denoeud-Ndam, L., Doritchamou, J., Viwami, F., Salanti, A., Nielsen, M. A., Fievet, N., Massougbodji, A., Luty, A. J. F., & Deloron, P. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2105.141626 · Cited by 98
Self-citationNielsen, M. A., Pinto, V. V., Resende, M., Dahlbäck, M., Ditlev, S. B., Theander, T. G., & Salanti, A. (2009) · Infection and Immunity · doi:10.1128/iai.00159-09 · Cited by 92 · cited 4×
“Adult Wistar rats (Taconic) were injected via the sub-cutaneous route with 40 μg of recombinant protein in PBS and Freund’s complete adjuvant (Sigma-Aldrich) or Alhydrogel (Statens Serum Institute) followed by two booster injections of 20 μg of protein in Freund's incomplete adjuvant or Alhydrogel at 3-week intervals…”
MethodSelf-citation
Cited by
Mordmüller, B., Sulyok, M., Egger-Adam, D., Resende, M., de Jongh, W. A., Jensen, M. H., Smedegaard, H. H., Ditlev, S. B., Soegaard, M., Poulsen, L., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1140 · Cited by 154
Self-citationDesigning a VAR2CSA-based vaccine to prevent placental malaria
Fried, M., & Duffy, P. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.011 · Cited by 86
“A recent analysis of the cross reactivity of this form showed minimal activity against heterologous isolates selected for CSA binding [55].”
BackgroundWang, K., Dagil, R., Lavstsen, T., Misra, S. K., Spliid, C. B., Wang, Y., Gustavsson, T., Sandoval, D. R., Vidal-Calvo, E. E., Choudhary, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23254-1 · Cited by 52
Self-citationDoritchamou, J. Y. A., Herrera, R., Aebig, J. A., Morrison, R., Nguyen, V., Reiter, K., Shimp, R. L., MacDonald, N. J., Narum, D. L., Fried, M., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw197 · Cited by 35
Fried, M., Kurtis, J. D., Swihart, B., Morrison, R., Pond-Tor, S., Barry, A., Sidibe, Y., Keita, S., Mahamar, A., Andemel, N., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2258-9 · Cited by 30
Metadata
- Authors
- Nielsen, M. A., Resende, M., de Jongh, W. A., Ditlev, S. B., Mordmüller, B., Houard, S., Ndam, N. T., Agerbæk, M. Ø., Hamborg, M., Massougbodji, A., Issifou, S., Strøbæk, A., Poulsen, L., Leroy, O., Kremsner, P. G., Chippaux, J.-P., Luty, A. J. F., Deloron, P., Theander, T. G., Dyring, C., & Salanti, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-09-01
- Volume
- 10
- Issue
- 9
- Pages
- e0135406
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1905770058
- Cited by
- 48
- References
- 13
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. https://app.cochat.ai/papers/10.1371/journal.pone.0135406
- The paper
- Nielsen, M. A., Resende, M., de Jongh, W. A., Ditlev, S. B., Mordmüller, B., Houard, S., Ndam, N. T., Agerbæk, M. Ø., Hamborg, M., Massougbodji, A., Issifou, S., Strøbæk, A., Poulsen, L., Leroy, O., Kremsner, P. G., Chippaux, J.-P., Luty, A. J. F., Deloron, P., Theander, T. G., . . . Salanti, A. (2015). The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. PLOS ONE. https://doi.org/10.1371/journal.pone.0135406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.